FreeGuest Editorial Lung-MAP: A five-year recap on the first master protocol trial in cancer research February 21, 2020Vol.46 No.08By Roy S. Herbst, Lyudmila Bazhenova, Joel Neal and Saiama N. Waqar
FreeGuest Editorial Immunotherapy, precision medicine in lung cancer drive sharp decline in cancer mortality overall January 08, 2020Vol.46 No.02By Otis W. Brawley
FreeGuest Editorial FDA e-cigarette flavoring ban leaves a bad taste“Trump eroding role of science in government” January 03, 2020Vol.46 No.01By Alan Blum
FreeGuest Editorial Museum malignancy:What the Sacklers and Philip Morris have in common October 18, 2019Vol.45 No.39By Alan Blum
Guest Editorial Herceptin: What it took to make it happen September 20, 2019Vol.45 No.35By Robert Bazell
Guest Editorial Why CAR-T policymaking is broken, and why we need to fix it September 13, 2019Vol.45 No.34By Michael Kolodziej, Louis Jacques and Marc Samuels
FreeGuest Editorial Learning from suramin: A case study of NCI’s much-hyped cancer drug that crashed and burned—35 years ago August 09, 2019Vol.45 No.32By Cy Stein
Guest Editorial The cost of underfunding research and the lingering dread of unstable funding July 26, 2019Vol.45 No.30By Candace S. Johnson
Guest Editorial Community oncology at a glance;How we got here and where we are going July 19, 2019Vol.45 No.29By Michael Kolodziej
